Damora Therapeutics, Inc. - ROE
GLTO
Price:
$21.58
Market Cap:
$1.74B
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Industry
Medical - Pharmaceuticals
IPO Date
2020-10-28
Stock Exchange
NASDAQ
Ticker
GLTO
PE Ratio
[-1.78]
ROE
[-122.61%]
Current Ratio
[22.48]
Dividend Yield
[0%]
Enterprise Value
[1.21B]
Dividend History
The ROE as of July 2026 (TTM) for Damora Therapeutics, Inc. (GLTO) is -122.61%
According to Damora Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -122.61%. This represents a change of 185.63% compared to the average of -42.93% of the last 4 quarters.
Damora Therapeutics, Inc. (GLTO) Historical ROE (quarterly & annually)
How has GLTO ROE performed in the past?
The mean historical ROE of Damora Therapeutics, Inc. over the last ten years is -80.77%. The current -122.61% ROE has changed 51.82% with respect to the historical average. Over the past ten years (40 quarters), GLTO's ROE was at its highest in in the September 2019 quarter at 0%. The ROE was at its lowest in in the December 2025 quarter at -83.51%.
Average
-80.77%
Median
-81.31%
Minimum
-148.15%
Maximum
-21.05%
Damora Therapeutics, Inc. (GLTO) ROE by Quarter and Year
Discovering the peaks and valleys of Damora Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.04%
Maximum Annual ROE = -21.05%
Minimum Annual Increase = -72.05%
Minimum Annual ROE = -148.15%
| Year | ROE | Change |
|---|---|---|
| 2025 | -87.29% | -41.08% |
| 2024 | -148.15% | 24.90% |
| 2023 | -118.61% | 18.86% |
| 2022 | -99.79% | 126.04% |
| 2021 | -44.15% | 109.72% |
| 2020 | -21.05% | -72.05% |
| 2019 | -75.32% | 45.52% |
Damora Therapeutics, Inc. (GLTO) Average ROE
How has GLTO ROE performed in the past?
The current ROE of Damora Therapeutics, Inc. (GLTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-118.02%
5-year avg
-99.60%
10-year avg
-80.77%
Damora Therapeutics, Inc. (GLTO) ROE vs. Peers
How is GLTO’s ROE compared to its peers?
Damora Therapeutics, Inc.’s ROE is greater than TransCode Therapeutics, Inc. (-99.39%), greater than Phio Pharmaceuticals Corp. (-77.34%), greater than Aprea Therapeutics, Inc. (-59.54%), greater than Kiora Pharmaceuticals, Inc. (-59.30%), greater than IN8bio, Inc. (-96.39%), greater than Acurx Pharmaceuticals, Inc. (-153.93%), greater than Aptevo Therapeutics Inc. (-198.50%), less than Lyra Therapeutics, Inc. (1.21%), greater than Adial Pharmaceuticals, Inc. (-162.83%), greater than BioCardia, Inc. (-5456.14%),
| Company | ROE | Market cap |
|---|---|---|
| -99.39% | $5.25M | |
| -77.34% | $11.43M | |
| -59.54% | $4.03M | |
| -59.30% | $11.39M | |
| -96.39% | $10.26M | |
| -153.93% | $2.20M | |
| -198.50% | $8.70M | |
| 1.21% | $887.44K | |
| -162.83% | $3.02M | |
| -5456.14% | $4.49M |
Build a custom stock screener for Damora Therapeutics, Inc. (GLTO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Damora Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Damora Therapeutics, Inc. (GLTO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Damora Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Damora Therapeutics, Inc.'s ROE?
How is the ROE calculated for Damora Therapeutics, Inc. (GLTO)?
What is the highest ROE for Damora Therapeutics, Inc. (GLTO)?
What is the 3-year average ROE for Damora Therapeutics, Inc. (GLTO)?
What is the 5-year average ROE for Damora Therapeutics, Inc. (GLTO)?
How does the current ROE for Damora Therapeutics, Inc. (GLTO) compare to its historical average?